Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer

The Pharmacogenomics Journal volume 9, pages 202–207 (2009)Cite this article

Abstract

Recent studies have shown an association between the GNAS1 T393C polymorphism and clinical outcome for various solid tumors. In this study, we genotyped 51 patients from an observational trial on cisplatin/5-FU-based neoadjuvant radiochemotherapy of locally advanced esophageal cancer (cT2-4, Nx, M0) and genotyping was correlated with histomorphological tumor regression. The C-allele frequency in esophageal cancer patients was 0.49. Pearson's χ2-test showed a significant (P<0.05) association between tumor regression grades and T393C genotypes. Overall, 63% of the patients in the T-allele group (TT+CT) were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(−) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%. The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Pisani P, Parkin DM, Ferlay J . Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891–903.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ . Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.

    Article  PubMed  Google Scholar 

  3. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH . Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549–555.

    Article  CAS  PubMed  Google Scholar 

  4. Devesa SS, Blot WJ, Fraumeni Jr JF . Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–2053.

    Article  CAS  Google Scholar 

  5. Sherman CA, Turrisi AT, Wallace MB, Reed CE . Locally advanced esophageal cancer. Curr Treat Options Oncol 2002; 3: 475–485.

    Article  PubMed  Google Scholar 

  6. Kelsen DP . Multimodality therapy of esophageal cancer: an update. Cancer J 2000; 2: S177–S181.

    Google Scholar 

  7. Sherman CA, Turrisi AT, Wallace MB, Reed CE . Locally advanced esophageal cancer. Curr Treat Options Oncol 2002; 3: 475–485.

    Article  PubMed  Google Scholar 

  8. Prenzel KL, Konig A, Schneider PM, Schnickmann C, Baldus SE, Schroder W et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol 2007; 4: 954–959.

    Article  Google Scholar 

  9. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684–692.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Refaely Y, Krasna MJ . Multimodality therapy for esophageal cancer. Surg Clin North Am 2002; 82: 729–746.

    Article  PubMed  Google Scholar 

  11. Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R et al. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg 2003; 27: 1067–1074.

    PubMed  Google Scholar 

  12. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727–1733.

    Article  Google Scholar 

  13. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305–313.

    Article  CAS  PubMed  Google Scholar 

  14. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462–467.

    Article  CAS  PubMed  Google Scholar 

  15. Brucher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004; 30: 963–971.

    Article  CAS  PubMed  Google Scholar 

  16. Kelsen DP . Multimodality therapy of esophageal cancer: an update. Cancer J 2000; 6 (Suppl 2): S177–S181.

    PubMed  Google Scholar 

  17. Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004; 10: 3794–3799.

    Article  CAS  PubMed  Google Scholar 

  18. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176–182.

    Article  CAS  PubMed  Google Scholar 

  19. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789–3798.

    Article  CAS  PubMed  Google Scholar 

  20. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y . Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Phasiol 2001; 186: 1–10.

    Article  CAS  Google Scholar 

  21. Lehnert S . Modification of postirradiation survival of mammalian cells by intracellular cyclic AMP. Radiat Res 1975; 62: 107–116.

    Article  CAS  PubMed  Google Scholar 

  22. Grunicke H, Hofmann J, Maly K, berall F, Posch L, Oberhuber H et al. The phospholipid- and calcium-dependent protein kinase as a target in tumor chemotherapy. Adv Enzyme Regul 1989; 28: 201–215.

    Article  CAS  PubMed  Google Scholar 

  23. Mann SC, Andrews PA, Howell SB . Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991; 48: 866–872.

    Article  CAS  PubMed  Google Scholar 

  24. Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW et al. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 871–877.

    Article  CAS  PubMed  Google Scholar 

  25. Frey UH, Lummen G, Jager T, Jockel KH, Schmid KW, Rubben H et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006; 12: 759–763.

    Article  CAS  PubMed  Google Scholar 

  26. Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005; 11: 5071–5077.

    Article  CAS  PubMed  Google Scholar 

  27. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R et al. The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat 2007; 105: 311–317.

    Article  CAS  PubMed  Google Scholar 

  28. Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H et al. GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 2007; 9: 159–165.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS . Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10: 754–761.

    Article  PubMed  Google Scholar 

  30. Urschel JD, Vasan H . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538–543.

    Article  PubMed  Google Scholar 

  31. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005; 11: 8341–8347.

    Article  CAS  PubMed  Google Scholar 

  32. Yan L, Herrmann V, Hofer JK, Insel PA . Beta-adrenergic receptor/cAMP-mediated signaling and apoptosis of S49 lymphoma cells. Am J Physiol Cell Physiol 2000; 279: C1665–C1674.

    Article  CAS  PubMed  Google Scholar 

  33. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 2003; 88: 4413–4417.

    Article  CAS  PubMed  Google Scholar 

  34. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655–659.

    Article  CAS  Google Scholar 

  35. Krumins AM, Barber R . Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997; 54: 61–72.

    Article  CAS  PubMed  Google Scholar 

  36. Yang X, Lee Sr FY, Wand GS . Increased expression of Gs(alpha) enhances activation of the adenylyl cyclise signal transduction cascade. Mol Endocrinol 1997; 11: 1053–1061.

    CAS  PubMed  Google Scholar 

  37. Myklebust JH, Josefsen D, Blomhoff HK, Levy FO, Naderi S, Reed JC et al. Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J Cell Physiol 1999; 180: 71–80.

    Article  CAS  PubMed  Google Scholar 

  38. Srivastava RK, Srivastave AR, Cho-Chung YS . Synergistic effects of 8-Cl-cAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: induction of retinoic acid receptor beta. Mol Cell Biochem 2000; 204: 1–9.

    Article  CAS  PubMed  Google Scholar 

  39. Kim SY, Seo M, Oh JM, Cho EA, Juhnn YS . Inhibition of gamma ray-induced apoptosis by stimulatory heterotrimeric GTP binding protein involves Bcl-xL down-regulation in SH-SY5Y human neuroblastoma cells. Exp Mol Med 2007; 39: 583–593.

    Article  CAS  PubMed  Google Scholar 

  40. Eichholtz-Wirth H, Hietel B . Cisplatin resistence in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo. Br J Cancer 1994; 70: 579–584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Adelstein DJ, Rice TW, Becker M, MA, TJ, A et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 1997; 80: 1011–1020.

    Article  CAS  PubMed  Google Scholar 

  42. Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248–1252.

    Article  CAS  PubMed  Google Scholar 

  43. Langner K, Thomas M, Klinke F, Bosse U, Heinecke A, Muller KM et al. Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of “mediastinal downstaging”. Chirurg 2003; 74: 42–48.

    Article  CAS  PubMed  Google Scholar 

  44. Thomas M, Rube C, Semik M, von Eiff M, Freitag L, Macha HN et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 1185.

    Article  CAS  PubMed  Google Scholar 

  45. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM . Tumor regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997; 123: 469–477.

    Article  CAS  PubMed  Google Scholar 

  46. Baldus SE, Mönig SP, Schröder W, Metzger R, Lang S, Zirbes TK et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 2004; 25: 421–427.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Koeln Fortune Program and CIO/Faculty of Medicine, University of Cologne.

Author information

Authors and Affiliations

  1. Department of General, Visceral and Cancer Surgery, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany

    H Alakus, U Warnecke-Eberz, E Bollschweiler, S P Mönig, D Vallböhmer, J Brabender, A H Hölscher & R Metzger

  2. Institute of Pathology, University of Cologne, Cologne, Germany

    U Drebber

  3. Institute of Pathology, University of Düsseldorf, Düsseldorf, Germany

    S E Baldus

  4. Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany

    K Riemann & W Siffert

Authors
  1. H Alakus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Warnecke-Eberz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Bollschweiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S P Mönig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Vallböhmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Brabender
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. U Drebber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S E Baldus
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Riemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W Siffert
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A H Hölscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Metzger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Metzger.

Additional information

Duality of interest

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alakus, H., Warnecke-Eberz, U., Bollschweiler, E. et al. GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J 9, 202–207 (2009). https://doi.org/10.1038/tpj.2009.5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2009.5

Keywords

This article is cited by

Search

Advanced search

Quick links